A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation

Trial Profile

A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2016

At a glance

  • Drugs Elobixibat (Primary)
  • Indications Constipation
  • Focus Adverse reactions
  • Acronyms Echo-3
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 20 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Aug 2014 Planned End Date changed from 1 Nov 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 28 Aug 2014 Planned primary completion date changed from 1 Oct 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top